HAMAD GENERAL HOSPITAL

First-Ever RCT to Evaluate Human Albumin's Effectiveness in Aneurysmal Subarachnoid Hemorrhage Launches in Qatar

• Hamad General Hospital in Qatar initiates groundbreaking randomized controlled trial to assess human albumin's impact on clinical outcomes in aneurysmal subarachnoid hemorrhage patients. • The three-year study will enroll 84 patients to compare albumin-enhanced fluid management versus standard crystalloid therapy, focusing on reducing cerebral vasospasm and improving neurological outcomes. • The trial addresses a critical research gap, as aneurysmal subarachnoid hemorrhage affects working-age populations with up to 60% mortality rate in untreated cases.